Specialty medical injectable drug program updates: Vyvgart™, Tezspire™ and more
New specialty medical injectable guidelines and requirements announced.
- All states
Please review the following table to determine changes to our specialty medical injectable drug programs.
Specialty medical injectable drugs added to review at launch
|Drug Name||UnitedHealthcare Commercial||Treatment Uses|
|VyvgartTM||x||Indicated for the treatment of generalized myasthenia gravis (gMg) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.|
|TezspireTM||x||Indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.|
|ApretudeTM||x||Indicated for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.|
|Leqvio®||x||Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).|
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 -RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.
More updates for your clients
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.